No significant reduction seen in percent of patients with urgent care or emergency department visits or hospitalization.
Findings reported for patients seeking treatment for opioid use disorder from 2016 to 2020.
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
However, amoxicillin-clavulanate tied to higher risk for adverse events, particularly in younger children.
Travere Therapeutics will submit a supplemental New Drug Application for full approval of sparsentan in the first half of 2024.
Pegozafermin is an investigational glycoPEGylated analog of FGF21.
MWTX-003 is an investigational anti-TMPRSS6 designed to induce endogenous expression of hepcidin resulting in suppression of serum iron levels.
NexoBrid (anacaulase-bcdb) is now available for eschar removal in adults with deep partial thickness and/or full thickness thermal burns.